Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2033581rdf:typepubmed:Citationlld:pubmed
pubmed-article:2033581lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:2033581lifeskim:mentionsumls-concept:C0032824lld:lifeskim
pubmed-article:2033581lifeskim:mentionsumls-concept:C0033442lld:lifeskim
pubmed-article:2033581lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:2033581lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:2033581lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:2033581lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:2033581lifeskim:mentionsumls-concept:C0360703lld:lifeskim
pubmed-article:2033581pubmed:issue5lld:pubmed
pubmed-article:2033581pubmed:dateCreated1991-6-26lld:pubmed
pubmed-article:2033581pubmed:abstractTextThe synthesis of 22 (4-methanesulfonamidophenoxy)propanolamines and their testing on isolated guinea pig cardiac myocytes, on isolated preparations from guinea pig atria, and on rat blood pressure are described. Secondary amines in the series (11a-f) showed residual beta-blocking activity, whereas incorporation of N-methyl phenylalkyl and 4-phenyl alicyclic amine groups abolished beta-blocking activity but led to enhanced ability to block the channel conducting the delayed rectified potassium current, and hence produced an increase in the cardiac action potential duration (APD). Incorporation of hydrophobic Cl and CF3 groups further enhanced potassium channel blocking activity. Compounds 81 and 8m produced a significant increase in APD at nanomolar concentrations, with no effect on cardiac muscle conduction velocity, and hence merit further investigation as Class III antiarrhythmic agents. Methylation of the methanesulfonamido group abolished channel-blocking activity; 4-carboxy and 3-methanesulfonamido analogues retained activity but at a reduced level.lld:pubmed
pubmed-article:2033581pubmed:languageenglld:pubmed
pubmed-article:2033581pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2033581pubmed:citationSubsetIMlld:pubmed
pubmed-article:2033581pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2033581pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2033581pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2033581pubmed:statusMEDLINElld:pubmed
pubmed-article:2033581pubmed:monthMaylld:pubmed
pubmed-article:2033581pubmed:issn0022-2623lld:pubmed
pubmed-article:2033581pubmed:authorpubmed-author:GillE WEWlld:pubmed
pubmed-article:2033581pubmed:authorpubmed-author:TerrarD ADAlld:pubmed
pubmed-article:2033581pubmed:authorpubmed-author:DennisP DPDlld:pubmed
pubmed-article:2033581pubmed:authorpubmed-author:ConnorsS PSPlld:pubmed
pubmed-article:2033581pubmed:issnTypePrintlld:pubmed
pubmed-article:2033581pubmed:volume34lld:pubmed
pubmed-article:2033581pubmed:ownerNLMlld:pubmed
pubmed-article:2033581pubmed:authorsCompleteYlld:pubmed
pubmed-article:2033581pubmed:pagination1570-7lld:pubmed
pubmed-article:2033581pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:meshHeadingpubmed-meshheading:2033581-...lld:pubmed
pubmed-article:2033581pubmed:year1991lld:pubmed
pubmed-article:2033581pubmed:articleTitleThe synthesis and potassium channel blocking activity of some (4-methanesulfonamidophenoxy)propanolamines as potential class III antiarrhythmic agents.lld:pubmed
pubmed-article:2033581pubmed:affiliationPharmacology Department, Oxford University, England.lld:pubmed
pubmed-article:2033581pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:2033581lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2033581lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2033581lld:pubmed